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Abstract
Introduction: Measurement of serum digoxin concentrations before steady-state is reached results in a falsely low concentration, and may affect 
treatment safety. We evaluated the proportion of serum digoxin measurements performed before steady-state is reached and the reasons for 
inappropriate sampling in hospitalized patients. 
Materials and methods: Electronic medical records of patients hospitalized between January 2011 and December 2015 treated with oral digoxin, 
that had more than one digoxin measurement were included. Serum digoxin measurements performed before achievement of pharmacological 
steady state were considered as inappropriate. The chi-square and chi-square for trend tests were used to analyse the relationship between inappro-
priate measurements and age, gender, diagnosis, inpatient service, serum digoxin, potassium and creatinine concentrations.
Results: We evaluated 2065 hospital admissions for 1621 patients and 11,407 digoxin measurements. The time between consecutive measure-
ments was 1.9 ± 2.4 days and 97% of all measurements were classified as inappropriate. There was no releationship between patient age, gender, 
serum creatinine concentration and inappropriate measurement. As opposed to expected, inappropriate digoxin measurement was higher when 
potassium concentrations were within the normal range (P = 0.025). Share of inappropriate determinations of digoxin was higher when concen-
trations > 2.6 nmol/L were recorded (P < 0.05). These measurements were requested most often in coronary care unit and cardiology department. 
Conclusions: In our study, inappropriate serum digoxin measurement was found to be very high although only one of the appropriateness criteria 
was evaluated. The findings reveal the need for some strategies to prevent inappropriate measurements and reduce costs.
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Short communication
Introduction
Although not as frequent as previously, digoxin is 
still being used in the management of chronic atri-
al fibrillation and mild to moderate heart failure 
(1,2). For effective and safe treatment with digoxin, 
therapeutic drug monitoring (TDM) should be 
performed because of its complex pharmacoki-
netic profile, narrow therapeutic index and exten-
sive toxicity profile. 
TDM is defined as the measurement of drug con-
centrations that, with appropriate clinical pharma-
cological interpretation, will directly affect pre-
scribing procedures (3). Many factors contribute to 
an accurate and meaningful drug concentration 
measurement. One of them is correct sampling 
time. In general, blood should be drawn after 
steady state concentration is reached and just be-
fore the next dose (through concentration, 6-8 
hours after drug intake). The studies showed that 
the time to reach steady state for digoxin is ap-
proximately 1 week (5 times the elimination half 
life) (2-4). Therefore, one should wait for at least 7 
days before serum digoxin concentration is meas-
ured in cases when the treatment has just started 
or the dose has just been changed (3,5). Measure-
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ments performed with incorrect timing may pro-
duce misleading results which would lead to inap-
propriate change in clinical management of pa-
tients and waste economic resources (3,4). 
While evaluating serum digoxin concentrations, 
besides blood sampling time, patients’ factors that 
alter the pharmacokinetics and pharmacodynam-
ics of digoxin should be taken into consideration. 
Renal function is the major factor affecting serum 
digoxin concentrations (2-8). Metabolic abnormali-
ties such as hypokalemia, hypomagnesemia, and 
hypercalcemia change tissue sensitivity to digoxin 
and toxicity may occur even within “therapeutic” 
serum concentrations (2,7). Also, medications used 
by the patient should be evaluated since drug in-
teractions affect serum concentration of digoxin, 
usually through decreasing its renal clearance (2).
TDM for digoxin started nearly 50 years ago. How-
ever, inappropriate use of TDM for digoxin is still 
encountered despite so many years of practice. 
The present retrospective study was performed to 
assess the proportion of digoxin measurements in 
hospitalized patients not fulfilling accepted crite-
ria for blood sampling in correct time and to iden-
tify reasons for inappropriateness.
Materials and methods
Study design
This study was designed as a descriptive, retro-
spective, electronic medical records database re-
view at the Dokuz Eylul University Hospital. This 
study started after its approval by Dokuz Eylul Uni-
versity Ethics Committee for Non-Interventional 
Research and was performed in accordance with 
the Declaration of Helsinki. 
The data of the patients hospitalized in Dokuz Ey-
lul University Hospital between January 2011 and 
December 2015, treated with oral digoxin, and 
with more than one measurement of serum digox-
in concentration, were included in this study. Each 
hospital admittance of a single patient was consid-
ered separately. Outpatients, patients who had 
only one measurement of serum digoxin concen-
tration, and patients aged younger than 18 were 
excluded. 
Electronic medical records were reviewed by the 
first author to obtain the following information: 
date, age, gender, diagnosis, digoxin result, hospi-
tal service, potassium concentration, creatinine 
concentration and time elapsed since preceding 
digoxin measurement.
Appropriateness criteria for blood sampling
Correct sampling time for digoxin measurement is 
after steady state concentration is reached, which 
is approximately 7 days (3). Serum digoxin measure-
ments made sooner than 7 days after the first meas-
urement were considered as “inappropriate meas-
urements”. Other appropriateness criteria is that 
blood should be sampled 6-8 hours after drug in-
take (through concentration). In our series, since 
blood collections were performed early in the 
morning before intake of drugs, we assume that 
samples were drawn at "through concentration". 
Methods
Serum digoxin concentrations were measured by 
particle-enhanced turbidimetric immunoassay 
(PETIA) using the Architect c8000  (Abbott Diag-
nostics Inc, Santa Clara, USA) between 2010 and 
2013, by immuno-inhibition method with AU5800 
(Beckman Coulter Inc, Brea, USA) between 2013 
and 2015 in Dokuz Eylul University Central Labora-
tory. The therapeutic range of digoxin was defined 
as 1.0-2.6 nmol/L. Same trilevel internal quality 
control materials were used for both methods ac-
cording to recommended values (Lyphochek Ther-
apeutic Drug Monitoring Control, Cat no:450,  Bio-
Rad Laboratories Inc, Hercules, USA). The average 
coefficients of variation were 0.69% for Beckman 
Coulter assay and 0.66% for Abbott assay. The ac-
ceptance criteria for imprecision were < 0.25 total 
allowable error (TEa) (TEa for digoxin 20% accord-
ing to CLIA Requirements for Analytical Quality).
Statistical analysis
Data were presented as percentages, mean values 
with standard deviation or median with interquar-
tile range (IQR). Categorical comparisons were per-
formed using the chi-square and chi-square for 
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trend test. A 2-sided P value of 0.05 was consid-
ered statistically significant. Data were analysed 
using SPSS 15.0 for Windows (SPSS Inc., Chicago, 
IL, USA). 
Results
Table 1 presents data of patients, including 2065 
hospital admissions for 1621 patients and 11,407 
serum digoxin measurements (after the first meas-
urement).
The time between consecutive serum digoxin con-
centration measurements was 1 day (IQR: 1-2 days). 
Almost all measurements were found to be per-
formed within 7 days after the first measurement, 
which was defined as “inappropriate measure-
ment” (Table 2).
When we looked into the reasons for inappropri-
ate measurements, no association was found be-
tween measurement frequency and patient age, 
gender, serum creatinine concentration (P > 0.05, 
data not shown). When serum digoxin concentra-
tion exceeded 2.6 nmol/L, which is the threshold 
value for toxic findings in most patients, the share 
of inappropriate measurements of digoxin was 
higher (Table 3). The measurements were inappro-
priate in 95%, 97% and 98% of patients with atrial 
fibrillation (AF), heart failure (HF) and AF+HF, con-
secutively (P < 0.001, data not shown). 
Age, years 76 (18-109)
Female, N (%)   1094 (53)
Diagnosis, %
     atrial fibrillation
     heart failure
atrial fibrilation and heart failure





Total hospitalisation, N 2065
SDC measurements, N† 11,407
Age is presented as median (range).
* Other diagnoses by frequency: breathing abnormalities, 
heart beat abnormalities, chronic ischemic heart disease, 
respiratory failure, pneumonia. 
SDC - serum digoxin concentration. †Number of serum 
digoxin measurements after the first measurement.
Table 1. Characteristics of patients who had serum digoxin 
concentration measurements











7 days and  more 374 (3)
SDC - serum digoxin concentration. *Number of serum 
digoxin measurements after the first measurement.






< 1.0 (3911) 96
0.0011.0 - 2.6 (6744) 97
> 2.6 (752) 98
Total (11,407) 97
SDC - serum digoxin concentration. *chi-square for trend test.
N - number of serum digoxin measurements after the first 
measurement.  †Percent of rows.
Table 3. Frequency of inappropriate  serum digoxin concentra-
tion measurements
As opposed to expected, inappropriate serum di-
goxin measurement was higher when potassium 
concentrations were within the normal range 
(P = 0.025, data not shown). 
Out of the inpatient services, those ordering the 
highest number of inappropriate measurements 
were coronary care unit and the cardiology service 
(Table 4). 
Discussion
Studies have shown that serum digoxin concentra-
tion measurements are not frequently performed 
according to the accepted criteria (4). This study 
showed that similar inappropriate measurements 
still take place in a university teaching hospital set-
ting.
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Table 4. Inappropriate serum digoxin concentration measure-










Coronary CU (1971) 99 1 (1-1)




CVS (435) 94 1 (1-2)
Anesthesia ICU (488) 90 3 (3-4)
Other (2132) 93 1 (1-3)
P* < 0.001
Data are presented as median and interquartile range. ICU - 
Intensive Care Unit. Coronary CU - Coronary Care Unit.
CVS - Cardio-Vascular Surgery. Other services - a total of 34 
services including chest diseases, ICU of cardiothoracic
surgery, orthopedics and traumatology, gastroenterology. 
*chi-square test. N - number of serum digoxin measurements 
after the first measurement. †Percent of rows.
One of the main reasons for inappropriate meas-
urement of digoxin is the measurement of serum 
digoxin concentrations before steady state con-
centration is reached. Interpreting a result before 
reaching steady state is quite difficult and may be 
wrong leading to inappropriate treatment deci-
sions (9). In our study, 97% of the measurements 
were inappropriate. In other words, almost all 
measurements were made before waiting for the 
drug to reach steady state concentration. This ra-
tio is quite high when compared to the results of 
the other studies (76%, 35% and 19%) (7,8). 
Average number of digoxin measurements per pa-
tient during their stay at the hospital was 6.4 
(range 2-91) (data not shown) and most of the 
measurements (82%) were performed at 1 to 2 day 
intervals. In fact, if the patients under digoxin 
treatment are stable both clinically and biochemi-
cally, the suggested interval to perform measure-
ments extends as long as 10 months. It has been 
even stated that there is no need for routine fol-
low up as long as there is no suspicion for 
theurapeutic insufficiency or toxicity, no medical 
condition to affect serum digoxin concentrations 
has emerged, or no change in drug consumption 
has been reported (5). 
In our study as the serum concentration of digoxin 
increased, the inappropriate measurements in-
creased. This finding can be explained by the doc-
tors’ being highly concerned when the drug con-
centration is above therapeutic range. However, 
even in cases of digoxin toxicity such a frequent 
rate of measurement can not be justified (3,6). On 
the other hand, it is evident that inappropriate 
measurement ratio is still high (97%) even when 
serum concentration is within therapeutic range. 
The studies evaluating the reasons for inappropri-
ate orders of laboratory tests showed that the in-
fluencing factors might be the anxiety of the doc-
tors to make a mistake, their lack of experience, 
their lack of knowledge about appropriate use of 
the tests, their ordering the same test repeatedly 
before checking the result of the previous test, 
and the ease of access to laboratory tests (9). In our 
hospital, studies should be planned to find out the 
reasons for such high rates of inappropriate digox-
in and possible other drug measurements and 
preventive action plans should be put into prac-
tice in accordance with the results. 
Increased age, elevated serum creatinine concen-
tration, and hypokalemia are among the reasons 
for increased risk for digoxin toxicity (4,9,10). In our 
study, there was no relationship between age, cre-
atinine concentration and hypokalemia vs inap-
propriate measurement. Contrary to expectations, 
inappropriate measurement was higher when po-
tassium concentration was within normal range. 
This makes us believe that digoxin measurements 
might have been ordered along with other daily 
routine blood tests performed during patient’s 
stay at the hospital. 
Serum digoxin concentrations were measured at 
1.5 day intervals in coronary care unit, and at 1.6 
day intervals in cardiology service. Finding out 
that 65% of inappropriate measurements were or-
dered from cardiology service and coronary care 
unit invalidated our assumption that doctors in 
departments where digoxin is used more fre-
quently are more knowledgeable about the phar-
macokinetic properties of digoxin. Therefore, the 
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doctors in cardiology clinics should be informed 
of this issue in the first place. Furthermore, an eas-
ily accesible consultation system with clinical phar-
macology could be set in high volume clinics such 
as cardiology. 
Since there is no TDM request form in our univer-
sity, information was obtained from electronic pa-
tient database. Therefore, we did not know if the 
measurements were ordered with the proper indi-
cations or if the proper actions were taken after 
the results were obtained. The lack of evaluation 
on these appropriateness criteria is the limitation 
of the study. 
In conclusion, we found that 97% of serum digoxin 
measurements performed during the hospital stay 
of patients were inappropriate, and that 65% of in-
appropriate measurements were ordered from 
cardiology service and coronary care unit. 
We consider that the findings of the study are im-
portant since they draw attention to blood collec-
tion time in digoxin measurement and they reveal 
the need for a continuous medical education on 
TDM. TDM is a multidisciplinary team work includ-
ing clinicians, nurses, biochemists and pharmacol-
ogists. Accurate blood concentrations can only be 
obtained by collaboration between the members 
of the team and their education on TDM. Another 
importance of the study is that it emphasizes the 
need for guidelines for serum drug concentration 
measurements and a TDM service. It also shows 
the need for upgrading electronic request forms 
to notify the user when the request is inappropri-
ate. Increased awareness of appropriate use of 
TDM will prevent misleading laboratory test re-
sults, and will lead to considerable savings in 
health budget. 
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